Analysis of vaccine-induced T cells in humans with cancer

Stefanie L. Slezak, Andrea Worschech, Ena Wang, David F. Stroncek, Francesco M. Marincola

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means of eliciting tumor-specific immune responses to mediate tumor regression and clearance. Developing vaccines targeted against cancer became an important focus as a therapy following the success of viral vaccines in preventing infection and disease. In humans with cancer, similar to viral infections, the host immune system is capable of recognizing antigens expressed on tumor cells. This similarity allows the immunological framework of the viral vaccine to be adapted to the cancer setting in hopes of enhancing human T-cell reactivity against tumor.1 It is generally believed that a requirement for tumor destruction to occur is the induction of sufficient levels of immune cells with high avidity for recognition of tumor antigens. Moreover, the cells must be targeted to the tumor site and be capable of infiltrating tumor stroma. 2 Several tumor-associated antigens (TAA) have been identified in the melanoma model which has allowed for immunization trials to evaluate therapeutic potential of tumor-specific T-cell induction. Some clinical trials reported limited success of T-cell mediated tumor rejection, reporting partial or complete regression in 10 to 30% of patients.3 Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specific T-cell induction indeed occurs but alone is not adequate to induce tumor regression.1 Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means of eliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion.

Original languageEnglish
Title of host publicationMemory T Cells
Pages178-188
Number of pages11
Volume684
DOIs
Publication statusPublished - 2010
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume684
ISSN (Print)00652598

Fingerprint

T-cells
Tumors
Vaccines
T-Lymphocytes
Neoplasms
Immunization
Neoplasm Antigens
Viral Vaccines
Vaccination
Antigens
Immunology
Active Immunotherapy
Immune system
Virus Diseases

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Slezak, S. L., Worschech, A., Wang, E., Stroncek, D. F., & Marincola, F. M. (2010). Analysis of vaccine-induced T cells in humans with cancer. In Memory T Cells (Vol. 684, pp. 178-188). (Advances in Experimental Medicine and Biology; Vol. 684). https://doi.org/10.1007/978-1-4419-6451-9_14

Analysis of vaccine-induced T cells in humans with cancer. / Slezak, Stefanie L.; Worschech, Andrea; Wang, Ena; Stroncek, David F.; Marincola, Francesco M.

Memory T Cells. Vol. 684 2010. p. 178-188 (Advances in Experimental Medicine and Biology; Vol. 684).

Research output: Chapter in Book/Report/Conference proceedingChapter

Slezak, SL, Worschech, A, Wang, E, Stroncek, DF & Marincola, FM 2010, Analysis of vaccine-induced T cells in humans with cancer. in Memory T Cells. vol. 684, Advances in Experimental Medicine and Biology, vol. 684, pp. 178-188. https://doi.org/10.1007/978-1-4419-6451-9_14
Slezak SL, Worschech A, Wang E, Stroncek DF, Marincola FM. Analysis of vaccine-induced T cells in humans with cancer. In Memory T Cells. Vol. 684. 2010. p. 178-188. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-6451-9_14
Slezak, Stefanie L. ; Worschech, Andrea ; Wang, Ena ; Stroncek, David F. ; Marincola, Francesco M. / Analysis of vaccine-induced T cells in humans with cancer. Memory T Cells. Vol. 684 2010. pp. 178-188 (Advances in Experimental Medicine and Biology).
@inbook{3148ba52622c4f49931e43b1f7040958,
title = "Analysis of vaccine-induced T cells in humans with cancer",
abstract = "Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means of eliciting tumor-specific immune responses to mediate tumor regression and clearance. Developing vaccines targeted against cancer became an important focus as a therapy following the success of viral vaccines in preventing infection and disease. In humans with cancer, similar to viral infections, the host immune system is capable of recognizing antigens expressed on tumor cells. This similarity allows the immunological framework of the viral vaccine to be adapted to the cancer setting in hopes of enhancing human T-cell reactivity against tumor.1 It is generally believed that a requirement for tumor destruction to occur is the induction of sufficient levels of immune cells with high avidity for recognition of tumor antigens. Moreover, the cells must be targeted to the tumor site and be capable of infiltrating tumor stroma. 2 Several tumor-associated antigens (TAA) have been identified in the melanoma model which has allowed for immunization trials to evaluate therapeutic potential of tumor-specific T-cell induction. Some clinical trials reported limited success of T-cell mediated tumor rejection, reporting partial or complete regression in 10 to 30{\%} of patients.3 Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specific T-cell induction indeed occurs but alone is not adequate to induce tumor regression.1 Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means of eliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion.",
author = "Slezak, {Stefanie L.} and Andrea Worschech and Ena Wang and Stroncek, {David F.} and Marincola, {Francesco M.}",
year = "2010",
doi = "10.1007/978-1-4419-6451-9_14",
language = "English",
isbn = "9781441964502",
volume = "684",
series = "Advances in Experimental Medicine and Biology",
pages = "178--188",
booktitle = "Memory T Cells",

}

TY - CHAP

T1 - Analysis of vaccine-induced T cells in humans with cancer

AU - Slezak, Stefanie L.

AU - Worschech, Andrea

AU - Wang, Ena

AU - Stroncek, David F.

AU - Marincola, Francesco M.

PY - 2010

Y1 - 2010

N2 - Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means of eliciting tumor-specific immune responses to mediate tumor regression and clearance. Developing vaccines targeted against cancer became an important focus as a therapy following the success of viral vaccines in preventing infection and disease. In humans with cancer, similar to viral infections, the host immune system is capable of recognizing antigens expressed on tumor cells. This similarity allows the immunological framework of the viral vaccine to be adapted to the cancer setting in hopes of enhancing human T-cell reactivity against tumor.1 It is generally believed that a requirement for tumor destruction to occur is the induction of sufficient levels of immune cells with high avidity for recognition of tumor antigens. Moreover, the cells must be targeted to the tumor site and be capable of infiltrating tumor stroma. 2 Several tumor-associated antigens (TAA) have been identified in the melanoma model which has allowed for immunization trials to evaluate therapeutic potential of tumor-specific T-cell induction. Some clinical trials reported limited success of T-cell mediated tumor rejection, reporting partial or complete regression in 10 to 30% of patients.3 Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specific T-cell induction indeed occurs but alone is not adequate to induce tumor regression.1 Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means of eliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion.

AB - Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means of eliciting tumor-specific immune responses to mediate tumor regression and clearance. Developing vaccines targeted against cancer became an important focus as a therapy following the success of viral vaccines in preventing infection and disease. In humans with cancer, similar to viral infections, the host immune system is capable of recognizing antigens expressed on tumor cells. This similarity allows the immunological framework of the viral vaccine to be adapted to the cancer setting in hopes of enhancing human T-cell reactivity against tumor.1 It is generally believed that a requirement for tumor destruction to occur is the induction of sufficient levels of immune cells with high avidity for recognition of tumor antigens. Moreover, the cells must be targeted to the tumor site and be capable of infiltrating tumor stroma. 2 Several tumor-associated antigens (TAA) have been identified in the melanoma model which has allowed for immunization trials to evaluate therapeutic potential of tumor-specific T-cell induction. Some clinical trials reported limited success of T-cell mediated tumor rejection, reporting partial or complete regression in 10 to 30% of patients.3 Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specific T-cell induction indeed occurs but alone is not adequate to induce tumor regression.1 Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means of eliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion.

UR - http://www.scopus.com/inward/record.url?scp=77956812290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956812290&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-6451-9_14

DO - 10.1007/978-1-4419-6451-9_14

M3 - Chapter

SN - 9781441964502

VL - 684

T3 - Advances in Experimental Medicine and Biology

SP - 178

EP - 188

BT - Memory T Cells

ER -